Targeting c-Src kinase enhances tamoxifen's inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins

Cancer Chemotherapy and Pharmacology

Volumn 60, Issue 4, 2007, Pages 535-543

  Planas Silva, Maricarmen D ^a   Hamilton, Kecia N ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Bad; Breast cancer; c Myc; c Src tyrosine kinase; Cyclin D1; Estrogen receptor; Mcl 1

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; CYCLIN D1; ESTROGEN RECEPTOR; MYC PROTEIN; PROTEIN; PROTEIN BAD; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN TYROSINE KINASE; SERINE; TAMOXIFEN;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; INHIBITION KINETICS; MODULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RECEPTOR BLOCKING;

APOPTOSIS; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN D1; HUMANS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS PP60(C-SRC); TAMOXIFEN;

EID: 34447503864     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0398-z     Document Type: Article

References (50)

1. Ingle JN (2002) Sequencing of hormonal therapy in breast cancer. Breast J 8:332-337
2. Ali S, Coombes RC (2002) Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2:101-112
3. Clarke R, Leonessa F, Welch JN, Skaar TC (2001) Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 53:25-71
4. Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI (2006) Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 97:263-274
5. Planas-Silva MD, Bruggeman RD, Grenko RT, Smith JS (2006) Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer. Biochem Biophys Res Commun 341:73-81
6. Riggins RB, Thomas KS, Ta HQ, Wen J, Davis RJ, Schuh NR, Donelan SS, Owen KA, Gibson MA, Shupnik MA, Silva CM, Parsons SJ, Clarke R, Bouton AH (2006) Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b. Cancer Res 66:7007-7015
7. Irby RB, Yeatman TJ (2000) Role of Src expression and activation in human cancer. Oncogene 19:5636-5642
8. Summy JM, Gallick GE (2003) Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22:337-358
9. Myoui A, Nishimura R, Williams PJ, Hiraga T, Tamura D, Michigami T, Mundy GR, Yoneda T (2003) C-Src tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res 63:5028-5033
10. Ishizawar R, Parsons SJ (2004) c-Src and cooperating partners in human cancer. Cancer Cell 6:209-214
11. Yeatman TJ (2004) A renaissance for SRC. Nat Rev Cancer 4:470-480
12. Summy JM, Gallick GE (2006) Treatment for advanced tumors: Src reclaims center stage. Clin Cancer Res 12:1398-1401
13. Feng W, Webb P, Nguyen P, Liu X, Li J, Karin M, Kushner PJ (2001) Potentiation of estrogen receptor activation function 1 (AF-1) by SRC/JNK through a serine 118- independent pathway. Mol Endocrinol 15:32-45
14. Shah YM, Rowan BG (2005) The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor a promoter interaction and elevated steroid receptor coactivator 1 activity. Mol Endocrinol 19:732-748
15. Castoria G, Migliaccio A, Bilancio A, Di Domenico M, de Falco A, Lombardi M, Fiorentino R, Varricchio L, Barone MV, Auricchio F (2001) PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J 20:6050-6059
16. Sisci D, Aquila S, Middea E, Gentile M, Maggiolini M, Mastroianni F, Montanaro D, Ando S (2004) Fibronectin and type IV collagen activate ERa AF-1 by c-Src pathway: effect on breast cancer cell motility. Oncogene 23:8920-8930
17. Song RX-D, Zhang Z, Santen RJ (2005) Estrogen rapid action via protein complex formation involving ERa and Src. Trends Endocrinol Metab 16:347-353
18. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112
19. Planas-Silva MD, Weinberg RA (1997) Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol Cell Biol 17:4059-4069
20. ras /Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J 17:2008-2018
21. Nam J-S, Ino Y, Sakamoto M, Hirohashi S (2002) Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin Cancer Res 8:2430-2436
22. Park HB, Golubovskaya V, Xu L, Yang X, Lee JW, Scully S II, Craven RJ, Cance WG (2004) Activated c-Src increases adhesion, survival and a2-integrin expression in human breast cancer cells. Biochem J 378:559-567
23. Acconcia F, Barnes CJ, Kumar R (2006) Estrogen and tamoxifen induce cytoskeletal remodeling and migration in endometrial cancer cells. Endocrinology 147:1203-1212
24. Mandlekar S, Kong A-NT (2000) Mechanisms of tamoxifen-induced apoptosis. Apoptosis 6:469-477
25. Richardson A, Malik RK, Hildebrand JD, Parsons JT (1997) Inhibition of cell spreading by expression of the C-terminal domain of focal adhesion kinase (FAK) is rescued by coexpression of Src or catalytically inactive FAK: a role for paxillin tyrosine phoshorylation. Mol Cell Biol 17:6906-6914
26. Butt AJ, McNeil CM, Musgrove EA, Sutherland RL (2005) Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer 12:S47-S59
27. Lu R, Serrero G (2001) Mediation of estrogen mitogenic effect in human breast cancer MCF-7 cells by PC-cell-derived growth factor (PCDGF/granulin precursor). Proc Natl Acad Sci USA 98:142-147
28. Wolter KG, Hsu Y-T, Smith CL, Nechushtan A, Xi X-G, Youle RJ (1997) Movement of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol 139:1281-1292
29. Teixeira C, Reed JC, Pratt MAC (1995) Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 55:3902-3907
30. Huang Y, Ray S, Reed JC, Ibrado AM, Tang C, Nawabi A, Bhalla K (1997) Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res Treat 42:3-81
31. Perillo B, Sasso A, Abbondanza C, Palumbo G (2000) 17ß-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol Cell Biol 20:2890-2901
32. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL (1994) bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 69:135-139
33. Diel P, Smolnikar K, Michna H (1999) The pure antiestrogen ICI 182780 is more effective in the induction of apoptosis and down regulation of BCL-2 than tamoxifen in MCF-7 cells. Breast Cancer Res Treat 58:87-97
34. Yang Q, Sakurai T, Jing X, Utsunomiya H, Shan L, Nakamura Y, Nakamura M, Oura S, Suzuma T, Yoshimura G, Umemura T, Kokawa Y, Kakudo K (1999) Expression of Bcl-2, but not Bax, correlates with estrogen receptor status and tumor proliferation in invasive breast carcinoma. Pathol Int 49:775-780
35. Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, Chang A, Kraker A, Jove R, Yu H (2002) Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 21:7001-7010
36. Craig RW (2002) MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia 16:444-454
37. Fernando RI, Wimalasena J (2004) Estradiol abrogates apoptosis in breast cancer cells through inactivation of BAD: ras-dependent nongenomic pathways requiring signaling through ERK and Akt. Mol Biol Cell 15:3266-3284
38. Chen T, George JA, Taylor CC (2006) Src tyrosine kinase as a chemotherapeutic target: is there a clinical case? AntiCancer Drugs 17:123-131
39. 1/S transition. Proc Acad Sci USA 103:2695-2700
40. Eischen CM, Packham G, Nip J, Fee BE, Hiebert SW, Zambetti GP, Cleveland JL (2001) Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1. Oncogene 20:6983-6993
41. Pratesi G, Perego P, Zunino F (2001) Role of Bcl-2 and its post-transcriptional modification in response to antitumor therapy. Biochem Pharmacol 61:381-386
42. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S, Adams JM, Roberts AW, Huang DCS (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10:389-399
43. Bingle CD, Craig RW, Swales BM, Singleton V, Zhou P, Whyte MKB (2000) Exon skipping in Mcl-1 results in a Bcl-2 homology domain 3 only gene product that promotes cell death. J Biol Chem 275:22136-22146
44. Herrant M, Jacquel A, Marchetti S, Belhacene N, Colosetti P, Luciano F, Auberger P (2004) Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. Oncogene 23:7863-7873
45. Jamil S, Sobouti R, Hojabrpour P, Raj M, Kast J, Duronio V (2005) A proteolytic fragment of Mcl-1 exhibits nuclear localization and regulates cell growth by interaction with Cdk1. Biochem J 387:659-667
46. Marriott HM, Bingle CD, Read RC, Braley E, Kroemer G, Hellewell PG, Craig RW, Whyte MKB, Dockrell DH (2005) Dynamic changes in Mcl-1 expression regulate macrophage viability or commitment to apoptosis during bacterial clearance. J Clin Invest 115:359-368
47. Weng C, Li Y, Xu D, Shi Y, Tang H (2005) Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells. J Biol Chem 280:10491-10500
48. Cowell LN, Graham JD, Bouton AH, Clarke CL, O'Neill GM (2006) Tamoxifen treatment promotes phosphorylation of the adhesion molecules, p130Cas/BCAR1, FAK and Src, via an adhesion-dependent pathway. Oncogene 25:7597-7607
49. Sharma SV, Gajowniczek P, Way IP, Lee DY, Jiang J, Yuza Y, Classon M, Haber DA, Settleman J (2006) A common signaling cascade may underlie "addiction" to the Src, BCR-ABL,and EGF receptor oncogenes. Cancer Cell 10:425-435
50. Recchia I, Rucci N, Funari A, Miggliaccio S, Taranta A, Longo M, Kneissel M, Susa M, Fabbro D, Teti A (2004) Reduction of c-Src activity by substituted 5,7-diphenyl-pyrrolo [2,3-d]-pyrimidines induces osteoclast apoptosis in vivo and in vitro. Involvement of ERK 1/2 pathway. Bone 34:65-79